{"id":6326,"date":"2024-02-26T01:09:50","date_gmt":"2024-02-26T01:09:50","guid":{"rendered":"https:\/\/economicherald.net\/?p=6326"},"modified":"2024-02-26T01:09:50","modified_gmt":"2024-02-26T01:09:50","slug":"asx-health-stocks-recce-cynata-say-their-diabetic-foot-ulcer-trials-are-going-great-guns","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=6326","title":{"rendered":"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns"},"content":{"rendered":"<p>Recce Pharma says Phase 1\/2 study is achieving primary endpoints<br \/>\nCynata also reports also reports good progress in Phase 1<br \/>\nCardiex is back on the ASX!<\/p>\n<p>\u00a0<\/p>\n<h2>Recce to expand diabetes foot ulcer Phase 1\/2 trial<\/h2>\n<p>An independent Safety Committee has unanimously agreed that <strong><a href=\"https:\/\/stockhead.com.au\/company\/recce-pharmaceuticals-rce\/\">Recce Pharma\u2019s (ASX:RCE)<\/a><\/strong> Phase I\/II clinical trial is safe, well tolerated and fit for expanded access.<\/p>\n<p>Recce\u2019s\u00a0<strong>Phase I\/II Diabetic Foot Infection (DFI) clinical trial<\/strong> is achieving its primary endpoints, and the independent <strong>Safety Committee of Liverpool Hospital NSW<\/strong> has now recommended its expansion to more patients, based on the interim data of the patients that were successfully treated with RECCE 327 (R327).<\/p>\n<p>R327 is a non-invasive method to treat diabetic foot ulcer infections. The drug\u2019s\u00a0potential as a topical broad-spectrum, anti-infective treatment is the objective of this clinical trial.<\/p>\n<p>Initial results from the trial show that administering R327 daily or once every second day resolved or even cured bacterial infections in diabetic foot ulcers.<\/p>\n<p>Of the estimated 537 million people worldwide who have diabetes, 19% to 34% will develop a diabetic foot ulcer (DFU) in their lifetime.<\/p>\n<p>Approximately 20% of people who develop a DFU will require lower-extremity amputation, either minor (below the ankle), major (above the ankle), or both.<\/p>\n<p>\u201cIt gives hope to better patient outcomes and avoiding limb amputation, as is so commonly the case with these complicated patients,\u201d said <em>Professor Hugh Dickson, the principal investigator <\/em>of the trial.<\/p>\n<p>\u00a0<\/p>\n<h2>Cynata\u2019s drug reduces wound surface area in diabetic foot ulcers<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/cynata-therapeutics-cyp\/\">Cynata Therapeutics (ASX:CYP)<\/a><\/strong> has also updated the market on the progress of its diabetic foot ulcers clinical trial.<\/p>\n<p>Cynata said it has completed its initial analysis of wound surface area in the first 16 patients in its <strong>Phase 1 clinical trial of CYP-006TK in DFU<\/strong>, up to the 10-week follow-up time point.<\/p>\n<p>Results show that the median percentage reduction in wound surface area in patients taking CYP-006TK group after 10 weeks was <strong>87.6%<\/strong>, compared to 51.1% in the control group.<\/p>\n<p>For clarity, a 100% reduction in wound surface area means complete wound healing.<\/p>\n<p>These findings are consistent with the results observed from the first six patients enrolled in this trial up to Day 28, which were released in April 2023.<\/p>\n<p>\u201cThese initial results are very promising, and consistent with the previous data readout,\u201d said <em>Dr Jolanta Airey, Cynata\u2019s chief medical officer.<\/em><\/p>\n<p>\u201cWe look forward to completing enrolment in the near future, which will take us a step closer to our objective of demonstrating safety and efficacy of CYP-006TK in DFU.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>CardieX has come out of a 5-month voluntary suspension<\/h2>\n<p>Meanwhile, <strong><a href=\"https:\/\/stockhead.com.au\/company\/cardiex-cdx\/\">Cardiex (ASX:CDX)<\/a><\/strong> has re-listed on the ASX, with its shares available for trading starting today.<\/p>\n<p>CardieX has been on voluntary suspension since September 2023, when the company withdrew its proposed Nasdaq listing due to negative market conditions in the US.<\/p>\n<p>Since that time, CardieX has completed a significant fund raising totalling around $14m, which gives the company a solid capital base going forward.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span><br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-recce-cynata-say-their-diabetic-foot-ulcer-trials-are-going-great-guns\/\">ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Recce Pharma says Phase 1\/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the <a href=\"https:\/\/economicherald.net\/?p=6326\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":6327,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-6326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=6326\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Recce Pharma says Phase 1\/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=6326\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-26T01:09:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns\",\"datePublished\":\"2024-02-26T01:09:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326\"},\"wordCount\":523,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=6326\",\"name\":\"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg\",\"datePublished\":\"2024-02-26T01:09:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=6326\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6326#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=6326","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns - Economic Herald","og_description":"Recce Pharma says Phase 1\/2 study is achieving primary endpoints Cynata also reports also reports good progress in Phase 1 Cardiex is back on the [more...]","og_url":"https:\/\/economicherald.net\/?p=6326","og_site_name":"Economic Herald","article_published_time":"2024-02-26T01:09:50+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=6326#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=6326"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns","datePublished":"2024-02-26T01:09:50+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=6326"},"wordCount":523,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=6326#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=6326","url":"https:\/\/economicherald.net\/?p=6326","name":"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=6326#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=6326#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg","datePublished":"2024-02-26T01:09:50+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=6326#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=6326"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=6326#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Recce-and-Cynata-update-the-market-with-their-diabetic-foot-ulcer-trials-today.-Picture-Getty-s8ZcEO.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=6326#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/6326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6326"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/6326\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/6327"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}